Amedisys Stock Forecast, Price & News

Amedisys' stock was trading at $170.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AMED shares have increased by 40.2% and is now trading at $239.01.
View which stocks have been most impacted by COVID-19.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amedisys.

Amedisys is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Amedisys.

Amedisys Inc (NASDAQ:AMED) posted its earnings results on Tuesday, July, 28th. The health services provider reported $1.34 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.81 by $0.53. The health services provider earned $485.06 million during the quarter, compared to analysts' expectations of $468.38 million. Amedisys had a return on equity of 22.41% and a net margin of 6.50%. The company's revenue was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.21 EPS.
View Amedisys' earnings history.

Amedisys updated its FY20 earnings guidance on Tuesday, July, 28th. The company provided earnings per share guidance of $4.84-5.06 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.54. The company issued revenue guidance of $2.04-2.07 billion, compared to the consensus revenue estimate of $2.03 billion.

14 analysts have issued 12 month price targets for Amedisys' shares. Their forecasts range from $160.00 to $290.00. On average, they expect Amedisys' stock price to reach $239.43 in the next twelve months. This suggests a possible upside of 0.2% from the stock's current price.
View analysts' price targets for Amedisys.

Amedisys saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 623,000 shares, a drop of 12.4% from the August 15th total of 710,900 shares. Based on an average daily trading volume, of 327,600 shares, the days-to-cover ratio is currently 1.9 days. Approximately 2.0% of the company's stock are short sold.
View Amedisys' Short Interest.

Some companies that are related to Amedisys include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), MEDNAX (MD), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Cisco Systems (CSCO), Micron Technology (MU), Pfizer (PFE), Johnson & Johnson (JNJ), Adobe (ADBE), CVS Health (CVS), Intel (INTC) and QUALCOMM (QCOM).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.44%), William Blair Investment Management LLC (3.04%), Riverbridge Partners LLC (2.08%), Bank of America Corp DE (1.39%), Marshall Wace North America L.P. (1.38%) and Bank of New York Mellon Corp (1.13%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Linda J Hall, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys.

AMED stock was sold by a variety of institutional investors in the last quarter, including Ninety One UK Ltd, Nuveen Asset Management LLC, Vanguard Group Inc., Federated Hermes Inc., Man Group plc, State of Wisconsin Investment Board, Victory Capital Management Inc., and Charles Schwab Investment Management Inc.. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, and Sharon Brunecz.
View insider buying and selling activity for Amedisys.

AMED stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Hudson Bay Capital Management LP, Goldman Sachs Group Inc., FMR LLC, Point72 Asset Management L.P., Robeco Institutional Asset Management B.V., Marshall Wace LLP, and Principal Financial Group Inc.. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys.

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMED stock can currently be purchased for approximately $239.01.

Amedisys has a market capitalization of $7.76 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe.

The official website for Amedisys is www.amedisys.com.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]